

Mechanism of Liver Regeneration During ALPPS

Yao Xiao ^{1,2,3,4†}, Lantao Peng^{5†}, Hongjuan Xu³, Ming Huang⁶, Chao Yang⁷, Guodong Liu^{1,4,8}, Xiwu Ouyang¹, Xiaoli Li^{1,2}, Yuanjing Wang^{1,2}, Langqing Sheng^{1,2}, Denggao Zhai^{1,2}, Ling Lin^{1,2}, Ling Liu^{1,2}, Gang Liu^{1,2} and Liansheng Gong^{1,2,3*}

¹Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China, ²International Joint Research Center of Minimally Invasive Endoscopic Technology Equipment and Standards, Changsha, China, ³Department of Nuclear Medicine, Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, China, ⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁵Department of General Surgery, Hunan Yueyang Maternal and Child Health-Care Hospital, Yueyang, China, ⁶Department of General Surgery, The First Hospital of Changsha, Changsha, China, ⁷Department of Hepatobiliary Surgery, Shanxi Bethune Hospital, Taiyuan, China, ⁸Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha, China

OPEN ACCESS

Edited by:

Yuyong Tan, Central South University, China

Reviewed by:

Liang Shi, Zhejiang University, China Jiasheng Chen, Shanghai Children's Hospital, China Dong Chen, Chinese Academy of Medical Sciences and Peking Union Medical College, China

*Correspondence:

Liansheng Gong gongliansheng8280@163.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology **Received:** 09 April 2022 **Accepted:** 26 April 2022 **Published:** 08 June 2022

Citation:

Xiao Y, Peng L, Xu H, Huang M, Yang C, Liu G, Ouyang X, Li X, Wang Y, Sheng L, Zhai D, Lin L, Liu L, Liu G and Gong L (2022) Mechanism of Liver Regeneration During ALPPS. Front. Cell Dev. Biol. 10:916286. doi: 10.3389/fcell.2022.916286 Liver cancer is one of the most lethal malignant tumors in the world, and surgical resection is the main treatment for liver cancer. Liver failure due to insufficient residual liver volume is a fatal complication after hepatectomy. How to effectively increase the residual liver volume after hepatectomy and improve the safety of hepatectomy has always been a problem to be solved in liver surgery. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) effectively reduces the occurrence of liver failure due to insufficient residual liver volume after hepatectomy, thereby increasing the probability of radical resection by inducing rapid proliferation of residual liver tissue. However, the molecular mechanism of residual liver tissue regeneration after primary ALPPS (combined liver partition and portal vein ligation) remains unclear. Here, we found that lots of circular RNAs (circRNAs) are upregulated after ALPPS in pig liver cells; then, we identified the orthologous circRNA in humans and pigs to detect their function in liver regeneration. The results showed that loss of circ-0067724 and circ-0016213 could suppress liver cell proliferation. Together, these findings suggest that circ-0067724 and circ-0016213 play an important role in liver cell proliferation, and this may help us to find new strategies to promote liver regeneration.

Keywords: circRNA, liver regeneration, ALPPS, cell proliferation, liver cancer (LC)

INTRODUCTION

Primary liver cancer (PLC) is one of the main malignant tumors that seriously endanger human health (Jemal et al., 2011; Bray et al., 2018). Based on the literature reports, the incidence and mortality of PLC are ranked fifth and second, respectively, in the world (Mattiuzzi and Lippi, 2020; Sung et al., 2021). PLC is the second most fatal and fourth most commonly diagnosed malignant tumor in China (Zheng et al., 2019). The American Cancer Society research studies show that there will be more than 40,000 new cases, and more than 30,000 new deaths of PLC occurred in the US in 2021 (Siegel et al., 2021).

The most effective treatment of liver cancer is surgical resection, but its initial resection rate is low (Shabunin et al., 2020). For patients with primary or metastatic liver tumors that are expected to have

insufficient future liver remnant (FLR), ALPPS may be considered for radical resection (Yao et al., 2014; Petrowsky et al., 2020). The German scholar Hans Schlitt found that the FLR was insufficient during the operation of a patient with hilar cholangiocarcinoma, so he temporarily decided to carry out a two-step hepatectomy with liver partition and right portal vein ligation in 2007 (Narita et al., 2012). Hauke Lang presented this procedure at the European-African Hepatobiliary and Pancreatic Conference in 2011. Schnitzbauer et al. (2012) published the relevant research results of ALPPS in 2012. This research result not only excites people but also raises many doubts. Reports on ALPPS increased rapidly after the 2015 ALPPS conference, which was held in Hamburg, Germany. Simultaneous portal and hepatic vein embolization (PVE/HVE) holds promise to induce accelerated liver regeneration in a similar safety profile to portal vein embolization (PVE). The demonstrated accelerated hypertrophy might increase the resectability. Randomized trials will have to compare PVE/HVE and PVE to determine if PVE/ HVE is superior to PVE (Heil and Schadde, 2021).

Circular RNA (circRNA) is a popular and special type of noncoding RNA molecule. The circRNA molecule has more stable expression than traditional linear RNA, and it is not easily degraded (Memczak et al., 2013). CircRNA has been well documented to play important roles in the regulation of cellular processes (Xiao et al., 2020). CircRNA works through microRNAs (miRNAs), and miRNAs are short in length (20–24 nt), which are major posttranscriptional regulators of gene expression. They form base pairs with the complementary target mRNA at the 3'UTR and modulate cellular processes by repressing the mRNA translation or degrading the mRNA (Salim et al., 2022).

Here, we found that loss of circ-0067724 and circ-0016213 can suppress liver cell proliferation. Together, these finding suggest that circ-0067724 and circ-0016213 play an important role in liver cell proliferation, and this may help us find new strategies to promote liver regeneration.

MATERIALS AND METHODS

Patient Section

The design of this study was approved by the Ethics Committee of XiangYa Hospital. All clinical data involved in this study were obtained with patient consent. A total of 12 liver cancer patients were included from January 2015 to December 2019. The patients with primary or metastatic liver tumors did not have insufficient future liver remnant (FLR). All patients underwent associating liver partition and portal vein ligation for staged hepatectomy and were diagnosed with primary (n = 8) or metastatic (n = 4) liver cancer by postoperative pathology. Patients with infectious diseases, autoimmune diseases, pregnancy, and liver cancer who previously underwent patients transarterial chemoembolization (TACE) or other treatments, and patients with incomplete data were excluded.

Animal Studies

Pigs were randomly divided into the control group, liver partition group, portal vein ligation group, and ALPPS group, and six pigs were

included in each group. All pigs were preoperatively fasted for 12 h and were fixed on the operating table after anesthesia. Ventral midline incision was around 10 cm long. We exposed the liver and hepatic portal vessels. 1) Control group: the abdominal cavity was disturbed without portal vein ligation and liver separation. 2) Liver partition group: the liver was separated with an electric knife. 3) Portal vein ligation group: the portal vein was separated, and the right branch of the portal vein was ligated. 4) ALPPS: the portal vein was separated, and the right branch of the portal vein was ligated. The ischemic line was separated with an electric knife (without damaging the hepatic portal vessels). The bleeding was stopped, and the abdomen was closed. The pigs grow freely. Animal experiments were approved by the Institutional Animal Care and Use Committee at the Xiangya Hospital of Central South University.

Residual Liver Volume Measurement

The liver volume was calculated using a CT scan (for human) or drainage method (for animal). Pigs were sacrificed after 2 weeks; the left liver was placed in a measuring cylinder filled with water, and the elevated volume of liquid represented the residual liver volume.

RNA Isolation and Library Preparation

For RNA extraction, the TRIzol reagent (Invitrogen) was used. RNA purity and quantification were evaluated using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, United States). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, United States).

Cell Culture

The human hepatocyte HL-7702 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen), with 10% FBS, 1% penicillin/streptomycin, and 1% glutamine. All cells were cultured in 5 percent (v/v) carbon dioxide in a humidified incubator at 37°C.

MTT Assay

The MTT assay was used to detect cell proliferation rates. Cells were transfected with plasmids for 24 h, and then seeded in 96-well plates at 5,000 per well. On day 2, we added the MTT reagent to each well and then incubated the plates at 37° C. After 2 h, we dissolved the precipitate in DMSO and measured the absorbance at 450 nm. Each sample was assayed in triplicate.

qRT-PCR Assay

The TRIzol reagent (Invitrogen) was used to extract the total RNA of cells, and 2 µg of total RNA was used for the reverse transcription. The Bio-Rad CFX96 system was used to conduct and calculate the expression of RNA. The data were normalized by GAPDH, and the relative expression was assessed by $2^{-\Delta\Delta CT}$ values. All primers were purchased from Integrated DNA Technologies, Inc. circ-0067724, F: TTTGTCCAGGATAGA CATAGAGC and R: ATGGGTTCACAGGCATTCTC; circ-0016213, F: TGGCAGTTCGAAAAAGAAAAA and R: GGC CCGAATCTCTTCCATA.



surgery. (c) CT scan showed the liver 2 weeks after the first-step hepatectomy on the patient. (d) Right hepatic tumor was completely resected. (H) Tumor was atrophic with ischemic necrosis. (l) Calculation of the left liver relative volume with a CT scan at four different time points: before operation, 1 week after the first-step operation, 2 weeks after the first-step operation, and 1 week after the second-step operation. The quantification is presented as mean \pm SD, ***p < 0.001.

Plasmid Construction

In the pLKO.1-shcircRNA plasmids, HL-7702 cells were transfected using the Lipofectamine 3000 transfection reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The pLKO.1-shcircRNA construct sequences are shown in **Supplementary Data**.

Statistical Analysis

All statistical analyses were carried out with SPSS 19.0 (SPSS Inc., Chicago, IL). All experiments were run with samples in triplicate and at least three separate times. The data values were presented as the mean \pm SD. Differences in mean values between two groups were analyzed by two-tailed Student's *t*-test. The p value < 0.05 was considered statistically significant.

RESULTS

ALPPS Could Promote Human Liver Regeneration

ALPPS is an innovative technique in liver surgery in recent years. In our study, we first operated ALPPS on liver cancer patients. All patients underwent CT examination to calculate the volume of the liver; the yellow arrow indicates the left liver at three different time points: before operation (**Figure 1A**), 2 weeks after the first-step operation (**Figure 1B**), and 1 week after the second-step operation (**Figure 1C**). The CT scan showed (**Figures 1A–C**) a significant increase in left liver volume (yellow arrow). During operation, we first separated the portal vein, and the right branch of the portal vein was ligated (**Figure 1D**). The ischemic line was seen in the middle lobe of the liver, and then, the ischemic line was separated with



an electric knife (without damaging the hepatic portal vessels) (Figure 1E). Two weeks later, the left liver (yellow arrow) was significantly enlarged (Figure 1F), so we performed a right hepatectomy on the patient. The right hepatic tumor was completely resected (Figure 1G), and the tumor was atrophic with ischemic necrosis (red arrow) (Figure 1H). The left liver grew rapidly in 2 weeks postoperatively (Figure 1I).

Together, the data from **Figure 1** indicated that ALPPS could promote human liver regeneration.

ALPPS Could Promote Pig Liver Regeneration

ALPPS could promote human liver regeneration (Tomassini et al., 2019), but the mechanism of its rapid and stable promotion of FLR regeneration in the short term remains unclear. Then, we operated ALPPS on pigs (Figure 2A), and the yellow arrow indicates the left liver. We took a CT scan of the pig to reconstruct the liver and 3D-printed it (Figure 2B). The left



FIGURE 3 | High-throughput sequencing for FLR. (A) CircRNA category of the high-throughput sequencing result. (B) CircRNA length of the high-throughput sequencing result. (C) Exon number per circRNA. (D) GC content frequency distribution of circRNA. (E) CircRNA numbers predicted in each sample.

liver (yellow arrow) was significantly enlarged (**Figure 2C**), and the right liver was atrophic with ischemic necrosis (red arrow). The CT scan showed the liver before surgery (**Figure 2D**), and 2 weeks later, the CT scan showed (**Figures 2E,F**) a significant increase in left liver volume (yellow arrow). The left liver increased more significantly in the ALPPS group than the portal vein ligation group; however, there was no change in the liver partition group contrast to the control group (**Figure 2G**). The left liver grew rapidly postoperatively (**Figure 2H**). Together, the data from **Figure 2** indicated that ALPPS could promote pig liver regeneration.

High-Throughput Sequencing for FLR

CircRNAs have been well documented to play important roles in promoting cancer progression. We collected preoperative and postoperative FLR tissue from pigs for high-throughput sequencing. The result showed that the circRNA category include antisense circRNA, exonic circRNA, intergenic circRNA, intronic circRNA, and sense-overlapping circRNA (**Figure 3A**). Most of the circRNA length is 201–700 bp (**Figure 3B**), and some of them are

circRNA_107				fol	d chai	nge	circ	base I	D	E				C	>					
	3 13:210781573_2	21081	9635_+	11.	33333	33		NA							Ĩ	2.0 -		3	•	
circRNA_292	4 6:156410969_1	56413 83111	339_+ 472 -		7.5			NA	_						ab				•	
circRNA_042	0 10:33071613_3	30784	65_+		7.5			NA							>	1.5		Т		т
circRNA_356	0 GL896372.1:104	40_16	337		7			NA							=	1.0 1	- -	m	_	曲.
circRNA_273	8 6:63478817_634 5 10:71294817_71	<u>49610</u> 13076	2 <u>-</u> 26 +		6.5	h	sa_cli	<u>c_000</u>	5829 7581		C	Irckina			ō		翩		- 🕅	
circRNA_334	6 9:38389524_384	42079	0_+	5. (666666	67	ba_err	NA	1001						ve	0.5-				
circRNA_005	8 1:58472238_585	51759	2_+		5.5			NA	-						ati					
circRNA_022	3 1:202612264_20 0 1:283819938_28	02619 83841	<u>933 -</u>		5.5	h	sa cir	NA 10.0088	8071						e	₀₀∄╂	ы;	L WUL B	Ø NU	Щ Ю
circRNA_093	3 13:98162592_98	81919	73_+		5.5	h	sa_cii	·c_006	7724						R	.0	9 e	1 20	· 22 4	3 ,5
circRNA_183	6 2:30477465_304	49190	2		4.75	_		NA			Splice juncti	on				04.60	12.8	610	22,19	3
circRNA_210	9 9:70888223 708	02415 89957	447		4.6			NA	_							000	000	0 00	00 00	00
circRNA_151	8 16:22541545_22	25482	12	4. 3	333333	33 h	sa_cii	.c_0002	2292		S	hcircRNA			~	In oll of	" clin	IL CH	ch ch	
circRNA_292	0 6:156189695 1	56190 00142	<u>959</u> 568	4. 2	<u>4 25</u>	:29 h	sa_cii	<u>c_001</u>	1983						91	5 5	5 5	5 5	5	
circRNA_040	5 10:27281192_27	72877	11_+		4			NA												
circRNA_131	6 15:28540273 28	85512	96		4			NA			р			Е						
circRNA_170	8 2:78551140 78	21020 55547	3_+		4			NA			5									
circRNA_295	7 7:21868824_218	86923	2_+		4			NA												
circRNA_310	4 7:124952565_12	24954 67482	675_+ 4 -		4	h	sa_cir	c_0033	$\frac{3115}{6213}$		- 15	HL-7702					HL	-7702	_ pLK	D
circRNA_345	0 9:140018765 14	40029	754_+		4			NA			. [5	shcirc-006772	4		sion		-		shci	rc-00 ⁻
											ă, 1.0-				bres	1.0	÷,			
											ě e				e ex				_	
											-6.0 satis				elativ	0.5-				
CircRNA	CircRNA (Top) - miRNA (Bottom) pairing	Site Type	CircRNA Start	CircRNA End	3' pairing	local AU	position		SPS CC	ontext+ si	<u>د م</u> م	ine 0007704			Å,	0.0	- 1	004004	10	
hindase ID hsa_circ_0057724 (5'	OUCOCOSIAAAAD SAATUCACAT									per		arc-0067724					circ-	001621	13	
5) hsa-miR-1257 (3' 5')	CCASSICUTOSSUASUAASUSA	7mer-1a	288	294	-0.006	-0.011	-0.027	0.000	0.034	-0.084										
hsa_circ_0057724 (5' 3')	CAUCODOUDARDURGAADACUUS	Trong-mill	99	105	0.003	-0.048	30.048	0.002	0.054	-0.157										
<u>hsa-miR-1264</u> (3' _ 5')	0000ccacoad001a00c0aac	11101 110		105		0.040					G									
hsa_circ_0057724 (5' 3')	GOCACCUUACCUUACUCCASAA	8mer-1a	323	330	0.013	-0.013	-0.070	0.034	-0.007	-0.29										
hsa-miR-1299 (3' 5') hsa_circ_0057724 (5'				1				-	-		Ch-DVA									
3)	OCADOGADOGOCADOGADOGADOGADOGADOGADOGADOGADOGADOGADOG	7mer-1a	255	261	0.001	-0.025	-0.023	0.010	-0.032	-0.143	CIFCRINA Mirihara ID	CircRNA (Top) - miRNA Site (Bottom) pairing Type	CircRNA Start	CircRNA End	3' pairing	ocal AU posit	ion TA	SPS	context+ score	scor
hsa_circ_0057724 (5' 3)	UUSAUUAACUCAAAAOCAGAGAGA										hsa_cic_0016213 (5"	UGAUUACUCACAUUUUCAGGAAU		-						percer
hsa-miR-326 (3' 5')	GACCUCCUCCCOSSUCUCC	/mer-1a	u	28	0.004	-0.015	-0.048	0.026	-0.048	-0.155	bsa-miR-1200 (3' - 5)	COCCOMBUCULACEOM/SUCCOC	31	37	-0.006	-0.013 -0.0	47 0.022	-0.034	-0.152	92
hsa_circ_0067724 (5' 37)	UUSAUUAACUCAAAAOCASAAAA	7mer-1a	22	28	0.001	-0.015	-0.048	0.026	-0.048	-0.158	hsa_circ_0016213 (5"	OCAGA/IGAAGA/UA/I-OGAAGAGA								
hsa-miR-330-5p (3" 5)	03340000303020300000											GACCUCUCUGUUCCCCUUCUCC	02	09		-0.012 -0.0		-0.039	-0.390	99
											hsa-miR-1236 (3' 5')				-0.018		99 0.037	100000		
3)	CUCCUUSAAUACUACUACUAAU	7mer-1a	352	358	-0.006	-0.016	-0.034	-0.023	0.010	-0.143	hsamiR-1236 (3° 5') hsa_circ_0016213 (5' 3')	AAAGAOODGAAGACGAAGAAGGA	188	195	0.003	0.044 .00	57 0.029	0.029	.0.209	96
hia_circ_0067724 (5 57) hia_circ_0067724 (5 57)		7mer-1a	352	358	-0.006	-0.016	-0.034	-0.023	0.010	-0.143	ha.miR.1226 (3' 5') hsa_cicc_0016213 (5' 3) hsa-miR-1248 (3' 5')	аадодогозадалскалаалоза аадосогозскорадалогоза аадосогозскорадналогосогоса 8mer-1a	168	195	0.003	0.044 -0.0	57 0.029	0.029	-0.209	96
ha_circ_0067224 (5 5) ha_miR-331-5p (3 5) hsa_circ_0067724 (5 1) hsa_miR-320 (3 5)		7mer-1a 7mer-1a	352	358 150	-0.006	-0.016	-0.034 -0.034	-0.023 0.020	0.010	-0.143	hasmift.1246 (3' 5) hsa.cicc.0016213 (5' 5) hsa.cicc.0016213 (5' 5) hsa.cicc.0016213 (5' 5) j)	AAA/3A/03003AA/3A/03A/03A 1111111 AAA/0300303010A/03AA/3A/030/00000000 00000000000000000000000 1010100000000	188	195	-0.003	0.044 -0.0	57 0.029 35 0.000	0.029	-0.209	96
hia_miR-331-5p (3' 5) hia_miR-331-5p (3' 5) hia_cic_0067724 (3' 5) hia_miR-370 (3' 5) hia_cic_0067724 (3' 3)	C000000038408404000840 11 1111 C03438405003930050300 10034403040504040405050 11111 00305054403009930005050 A58000004404000040000	7mer-1a 7mer-1a	352	358 150	-0.006 0.001	-0.016	-0.034 -0.034	-0.023 0.020	0.010	-0.143	ha.miti. 1226 (7 5) ha.c.ice, 0016211 (7 j) ha.miti.1249 (7 5) ha.miti.1249 (7 5) ha.miti.1249 (7 5)	алалалотототалалалара Алалототототалалалара осталотототототототототото солототототототототототототото утиет 1а	188	195	-0.003 -0.002	0.044 -0.0	57 0.029 55 0.000	0.029	-0.209	96 84
ma_cmi_00#22#16		7mer-1a 7mer-1a 7mer-1a	352 144 469	358 150 475	-0.006 0.001 0.008	-0.016 -0.013 -0.018	-0.034 -0.034 -0.047	-0.023 0.020 -0.010	0.010 -0.063 0.044	-0.143 -0.163 -0.097	has_mini_1226 (c ⁻ 5) has_toric_001621 (S ⁻ has_toric_001621 (S ⁻ has_toric_001621 (S ⁻ has_toric_001621 (S ⁻ has_toric_001621 (S ⁻ has_toric_001621 (S ⁻)	AAAG0000004ACCC-03A404A00A Bener-1a AAAG0000004ACCC-03A404A000 Bener-1a OOD000004ACCC-03A404A0000000 There-1a OOD0000004ACCC-03A404A00000000 There-1a AAA0000000000000000000000000000000000	188 141 124	195 147 130	-0018 0.003 -0.002 0.011	0.044 -0.0 0.020 -0.0 -0.020 -0.0	57 0.029 55 0.000 35 0.000	0.029	-0.209 -0.057 -0.246	96 84 89
Ina. (iii), (0.02.124 (5 5) Ina. (iii), (0.02724 (5 5))		7mer-1a 7mer-1a 7mer-1a 8mer-1a	352 144 469 32	358 150 475 39	-0.006 0.001 0.008	-0.016 -0.013 -0.018 0.046	-0.034 -0.034 -0.047 -0.106	-0.023 0.020 -0.010	0.010 -0.063 0.044	-0.143 -0.163 -0.097	hatemii 1226 (* - 5) hatemii 1227 (* - 5) hatemii 1227 (* - 5)	AAARDOVERANCE (TAARDAC) AAAROOVERANCE (TAARDAC) OCTOOVERANCE (TAARDAC) CAROOVERANCE (TAARDAC) CAROOVERANCE (TAARDAC) CAROOVERANCE (TAARDAC) CONTROLOGIC (188 141 124	195 147 130	-0.003 -0.002 0.011	0.044 -0.0 0.020 -0.0 -0.020 -0.0	57 0.029 55 0.000 35 0.000	0.029 0.034 -0.085	-0.209 -0.057 -0.246	96 84 89
Ina. (100, 000, 224 (5 5) Ina. (100, 000, 7224 (5 5)) Ina. (100, 724 (5 - 5)) Ina. (100, 724 (5 - 5))	сполотознанистронных станалоссоранистронных тознакоссоранистронных подположима востановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановороноссоронных состановоронных состановороноссоронных состановоронных соста	7mer-1a 7mer-1a 8mer-1a	352 144 469 32	358 150 475 39	-0.006 0.001 0.008 0.003	-0.016 -0.013 -0.018 0.046	-0.034 -0.034 -0.047 -0.106	-0.023 0.020 -0.010 0.037	0.010 -0.063 0.044 -0.063	-0.143 -0.163 -0.0977 -0.33	ham (BL220) (7 - 5) ham (GL220) (7 - 5) ham (GL2	ADALACIONALIZZA (CALANZA) Bere 1a ADALOSSIPICACIONALIZZA (CALANZA) France 1a ADALOSSIPICACIÓN (CALANZA) France 1a ADALOSSIPI	188 141 124 3	195 147 130 9	-0018 0.003 -0.002 0.011 too_close 1	0.044 -0.0 0.020 -0.0 -0.020 -0.0	57 0.029 57 0.029 35 0.000 37 -0.041 58 too_clo	0.029 0.034 0.034 -0.065	-0.209 -0.209 -0.057 -0.246 * too_close	96 84 89 NA
Internet (1997)		7mer-1a 7mer-1a 8mer-1a 7mer-1a	352 144 469 32 324	358 150 475 39 330	-0.006 0.001 0.008 0.003	-0.016 -0.013 -0.018 0.046 -0.014	-0.034 -0.034 -0.047 -0.106 -0.031	-0.023 0.020 -0.010 0.037 0.019	0.010 -0.063 0.044 -0.063	-0.143 -0.163 -0.0977 -0.33	has mB.220 (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5) has graphical (° - 5)		188 141 124 3	195 147 130 9	-0.018 0.003 -0.002 0.011 too_close t	0.044 -0.0 0.020 -0.0 -0.020 -0.0 0.020 too_c	57 0.029 57 0.029 35 0.000 37 -0.041 50 _clo	0.029 0.034 -0.085 e too_close	-0.209 -0.057 -0.246 too_close	96 84 89 NA
Interaction (Construction (Construction) Interaction (Con		7mer-1a 7mer-1a 8mer-1a 7mer-1a	352 144 469 32 324	358 150 475 39 330	-0.006 0.001 0.008 0.003 -0.009	-0.016 -0.013 -0.018 0.046 -0.014	-0.034 -0.034 -0.047 -0.106 -0.031	.0.023 0.020 .0010 0.037 0.019	0.010 -0.063 0.044 -0.063	.0.143	baseline.228 (* - 5) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7) bag.dr; (20124) (* - 7)	ADALACIONALIZZANICA	188 141 124 3 94	195 147 130 9 100	-0.003 -0.002 0.011 too_close 1 -0.006	0,044 -0.0 0,020 -0.0 -0.020 -0.0 -0.020 -0.0 0,002 -0.0	57 0.029 57 0.029 35 0.000 37 -0.041 05e too_do	0.029 0.034 0.085 0.085 0.085 0.007	-0.209 -0.209 -0.057 -0.246 too_close -0.248	96 84 89 NA
Inc. (CC. ORIZER (S 1)) (S 1), (S 1)		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a	352 144 469 32 324 497	358 150 475 39 330 503	-0.006 0.001 0.008 0.003 -0.009	-0.016 -0.013 -0.018 0.046 -0.014	-0.034 -0.034 -0.047 -0.106 -0.031 -0.050	-0.023 0.020 0.010 0.019 0.004	0.010 -0.063 0.044 -0.063 -0.034	0.143	has mill. 2020 -5.5 has age, goile 210 -5.7 has age, goile 210 -5.7 has age, goile 210 -5.7 has age, goile 210 -7.7	AMAGENETISANDES Bene 1 a AMAGENETISANDES Bene 1 a AMAGENETISANDES Bene 1 a CONTENTISANDES Ameri 1 a	188 141 124 3 94	195 147 130 9 100	-0.003 -0.002 0.011 too_close 1 -0.006	0.044 -0.0 0.020 -0.0 -0.020 -0.0 0.020 -0.0 0.020 -0.0	57 0.029 55 0.000 35 0.000 37 -0.041 50 -0.123	0.029 0.034 0.034 0.085 0.085 0.007	-0.209 -0.057 -0.246 too_close -0.248	96 84 89 NA 81
In a construction of a constru		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a	352 144 469 32 324 497	358 150 475 39 330 503	-0.006 0.001 0.008 0.003 -0.009 0.001	-0.016 -0.013 -0.018 0.046 -0.014 -0.033	-0.034 -0.034 -0.047 -0.106 -0.031 -0.050	-0.023 0.020 0.010 0.037 0.019 0.004	0.010 -0.063 0.044 -0.063 -0.034 0.019	.0.143	baseline.2020 -53 baseline.2020 -53<		168 141 124 3 94 25	195 147 130 9 100 31	-0.003 0.003 -0.002 0.011 too_close 1 -0.006 0.012	0.044 -0.00 0.020 -0.0 -0.020 -0.0 0.002 -0.0 0.002 -0.0	57 0.029 55 0.000 35 0.000 37 -0.041 iose too_clor 40 -0.123 58 0.016	0.029 0.034 0.034 0.085 0.007 0.056	-0.209 -0.057 -0.246 too_close -0.248 -0.248	96 84 89 NA 81 91
In a click (0.00124 (S = 1)) In a critic 0.00124 (S = 1)) In a critic 0.001724 (S = 1))		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a	352 144 469 32 324 497 94	358 150 475 39 330 503 100	-0.006 0.001 0.008 0.003 -0.009 0.001	-0.016 -0.013 -0.018 0.046 -0.014 -0.033	-0.034 -0.034 -0.047 -0.106 -0.031 -0.050	-0.023 0.020 0.037 0.037 0.019 0.004 0.027	0.010 -0.063 0.044 -0.063 -0.034 0.019	0.143	baseline.220 (-5) baseline.220 (-5) baseline.220 (-5) (-5) baseline.220 (-5)	AAAAAUUUUAAUUUAAUUU Beer 1a AAAUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU	188 141 124 3 94 25	195 147 130 9 100 31		0,044 -0.0 0,020 -0.0 -0.020 -0.0 0,020 -0.0 0,002 -0.0 0,009 -0.0	57 0.029 57 0.029 35 0.000 37 -0.041 58 0.016	0.029 0.034 -0.085 e too_close 0.007 0.056	-0.209 -0.057 -0.246 too_close -0.248 -0.085	95 84 89 NA 81 91
10 Calculation (Control Control Contro		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-m0	352 144 469 32 324 497 94	358 150 475 39 330 503 100	-0006 0.001 0.008 0.003 -0.009 0.001 -0.025	-0.016 -0.013 -0.018 0.046 -0.014 -0.033 -0.059	-0.034 -0.034 -0.047 -0.106 -0.031 -0.050 -0.049	-0.023 0.020 0.037 0.037 0.004 0.027 0.017	0.010 -0.063 0.044 -0.063 -0.034 0.019 0.095	0.1143	baseline.2020 -53 baseline.2020 -73 baseline.2020 -73<	هوی موسط المحلم ال محلم المحلم المحلم المحلم المحلم الم	188 141 124 3 94 25 331	195 147 130 9 100 31 337	0.003 0.001 0.001 0.001 0.000	0,044 -0.0 0,020 -0.0 0,020 -0.0 0,020 -0.0 0,020 -0.0 0,000 -0.0 0,020 -0.0	57 0.029 57 0.009 15 0.000 37 -0.041 0se too_cdor 40 -0.123 58 0.016 36 0.017	 0.029 0.034 0.036 0.065 0.056 0.053 	-0.209 -0.209 -0.057 -0.246 too_close co_close -0.248 -0.085	96 84 89 14 81 91 85
ан (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-1a	352 144 469 32 324 497 94 499	358 150 475 39 330 503 100 504	-0.006 0.001 0.008 0.003 -0.009 0.001 -0.025 0.001	-0.016 -0.013 -0.018 -0.016 -0.014 -0.033 -0.059	-0.034 -0.034 -0.047 -0.047 -0.050 -0.050	-0.023 0.020 0.037 0.037 0.001 0.027 0.017 0 0.017 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.010 -0.063 -0.063 -0.063 0.019 0.019 0.042	0.1143 1 0.0163 1 0.0077 1 0.313 1 0.1143 1 0.1131 1 0.0006 1	baseline.2020 -53 baseline.2020 -73 baseline.2020 -73<	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	188 141 124 3 94 25 331	195 147 130 9 100 31 337	0.003 -0.002 0.011 0.011 -0.006 0.012 0.003	0.044 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0	57 0.029 57 0.029 35 0.000 37 -0.041 iose too_clor 40 -0.123 58 0.016 36 0.017	 0.029 0.029 0.034 0.034 0.034 0.034 0.035 0.055 	-0.209 -0.209 -0.057 -0.246 too_close -0.248 -0.085	96 84 89 NA 81 91 85
1)		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-1a 7mer-1a	332 144 469 32 324 497 94 499 157	358 150 475 39 330 503 503 100 504 163	-0006 0.001 0.008 0.008 0.009 0.001 0.001	-0.013 -0.013 -0.018 0.046 -0.014 -0.014 -0.033 -0.059 -0.022	.0034 .0034 .0037 .0106 .0031 .0031 .0050 .0050 .0050	-0.023 0.020 0.017 0.017 0.017 0.017 0.001 0.017 0.002 0.002 0.001 0.002 0.002 0.00 0.00	0.010 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.143	baseline.226 (-5)	Abbase Beened Beenee Beenee Beenee<	168 141 124 3 94 25 331 196	195 147 130 9 100 31 337 204	0.003 0.003 0.011 0.01 0.01 0.012 0.003 0.00 0.0	0.044 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.024 -0.0	0037 0029 57 0.029 155 0.000 155 0.000 157 -0.041 158 0.016 158 0.017 156 0.017 157 0.015	0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.053	-0.209 -0.209 -0.657 -0.246 too_close 0.248 -0.085 -0.085	96 84 89 NAA 81 91 85 85 89
на полната		7mer-1a 7mer-1a 7mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-1a 7mer-1a	352 144 469 32 324 497 94 499 157	358 150 475 39 330 503 503 100 504 163	-0006 0.001 0.008 0.005 0.005 0.001 0.001	-0.013 -0.013 -0.018 0.046 -0.034 -0.033 -0.059 -0.022	.0394 .0094 .0097 .0106 .0091 .0090 .0090 .0090	-0.023 0.020 0.020 0.020 0.021 0.021 0.021 0.022	0.010 0.000	0.143 I 0.3163 I 0.317 I 0.313 I 0.113 I	baselb.220 -53 baselb.220 -53 baselb.220 -53 baselb.221 -57 baselb.222 -57 baselb.223 -77 baselb.232 -77	Amazana Amazana Amazana <	100 141 124 3 94 25 331 190	195 147 130 9 100 31 337 204		0.044 -0.02 0.020 -0.02 -0.020 -0.02 -0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02 0.020 -0.02	www.sector www.sector str www.sector	• • • •	-229 -029 -057 -0246 -0248 -0248 -0005 -0005	96 84 89 NA 81 91 85 85 89
ан полна по		7mer-1a 7mer-1a 8mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-1a 7mer-1a 7mer-1a	352 144 449 324 497 94 498 157 130	358 150 475 39 330 503 503 504 163 156	-0006 0.001 0.006 0.005 0.001 0.001 0.001 0.001 0.001	-0.013 -0.013 -0.018 0.046 -0.014 -0.033 -0.039 -0.022 0.045	.0394 .0094 .0094 .0097 .0099 .0099 .0099 .0099 .0093 .0094	-0.23	0.010 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.143	baselitit.2007 -53 baselit	AMAGENETISALACINATIONS Bene 1 a AMAGENETISALACINATIONS Bene 1 a AMAGENETISALACINATIONS Paner 1 a COLORCONSCIPALIZACINATIONS Paner 1 a AMAGENETISALACINATIONS Paner 2 a AMAGENETISALACINATIONS Paner 3 a AMAGENETISALACINATIONS Paner 4 a AMAGENETISALACINATIONS Pan	106 41 24 3 94 331 196 59	195 147 130 9 100 31 337 204 65		0.044 -0.0 0.020 -0.0 -0.020 -0.0 -0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.020 -0.0 0.022 -0.0 0.024 -0.0	37 0.029 37 0.029 35 0.000 37 -0.041 37 -0.041 37 -0.041 38 0.016 38 0.015 36 0.015 33 0.023	• • • •	 0.209 0.209 0.265 0.246 0.248 0.248 0.248 0.005 0.005 0.0127 	96 84 89 NA 81 91 85 85 89 91
A sector of the		7mer-1a 7mer-1a 8mer-1a 8mer-1a 7mer-1a 7mer-1a 7mer-1a 7mer-1a	332 144 469 32 324 497 94 499 157 159	358 150 475 39 330 503 100 504 163 156	-0006 0.001 0.006 0.005 0.009 0.001 0.001 0.001 0.001 0.001	-0.014 -0.014 -0.014 -0.014 -0.014 -0.019 -0.022 -0.022	.03)4 .03)4 .03)7	-0.023 0.029	0.0100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.143	hase BL 200 (-5.) hase BL 200 (-5.) hase Control (100 (-	Amaterican and an	188 141 124 3 94 25 331 198 59	195 147 130 9 100 31 337 204 65	0.003 0 0.003 0 0.011 0 0.001 0 0.003 0 0.003 0	0.944 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0 0.920 -0.0	37 0.029 37 0.029 35 0.000 37 0.029 35 0.000 36 0.017 36 0.015 35 0.023	0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.053 0.043	 0.209 0.209 0.057 0.246 0.248 0.048 0.048 0.048 0.048 0.048 0.041 0.041 	95 84 89 NA 81 91 85 85 89 94
A sector of the		Этися-1а Этися-1а Этися-1а Винея-1а Этися-1а	332 144 469 32 324 477 94 479 157 150	358 150 475 39 330 503 503 100 504 163 156	-006 0.001 0.005 0.003 0.001 0.005 0.001 0.001 0.001 0.001	-0.014 -0.018 0.046 -0.014 -0.033 -0.059 -0.022 0.065 -0.020	-034 -034 -047 -016 -031 -033 -035 -055 -055 -005	-0.023 0.029	0.0100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.143	baselit.200 -53 baselit.200 -74 baselit.200 -75 baselit.200	AMAMANUMANANANANANANANANANANANANANANANAN	188 141 124 3 3 94 25 331 196 99 99 99	195 147 130 9 100 31 337 204 65 500	0.003 0 0.003 0 0.011 0 0.011 0 0.004 0 0.003 0 0.004 0	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	www.sector www.sector str www.sector	0029 0029 0034 0034 0034 0034 0034 0034 0034 0035 0036 0036 0037 0036 0037 0036 0036 0037 0036 0037 0036 0037 0036 0037 0036 0037	-0.209 -0.577 -0.657 -0.246 -0.246 -0.246 -0.248 -0.248 -0.005 -0.005 -0.005 -0.0127 -0.019	96 84 89 NA 81 91 85 85 99 94 90
Marked Solution (S = 1) Marked Solution (S =		Prese-1a Prese-1a Prese-1a Brese-1a Brese-1a Prese-1a	352 144 449 32 324 497 94 497 94 498 157 150 157 433	358 150 475 39 330 503 503 100 504 163 163 439	-006 0.001 0.005 0.003 0.001 0.007 0.007 0.007	-0.014 -0.013 -0.018 -0.014 -0.014 -0.033 -0.033 -0.032 -0.022 -0.022 -0.025 -0.025 -0.020 -0.021	-034 -034 -04 -047 -046 -031 -035 -035 -035 -035 -035 -035 -035	.0.020 0 0.020 0 .0.010 0 0.021 0 0.024 0 0.027 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.027 0 0.026 0 0.027 0 0.027 0 0.027 0 0.026 0 0.027 0 0.027 0 0.027 0 0.028 0 0.029 0 0.029 0 0.029 0	0.0100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.101 0 0.101 0 0.207 0 0.313 0 0.314 0 0.315 0 0.317 0 0.318 0 0.319 0 0.319 0 0.319 0 0.321 0 0.325 0 0.334 0	baseline.202 (0 - 5) baseline.202 (0 - 1)	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	100 141 124 3 3 94 25 331 190 59 494	195 147 130 9 100 31 337 204 65 500		0.041 0.054 0.042 0.0 0.043 0.0 0.040 0.0 0.040 0.0 0.042 0.0 0.043 0.0 0.044 0.0 0.044 0.0 0.044 0.0 0.044 0.0	www.sector www.sector str www.sector	0.029 0.029 0.034 0.034 0.034 0.034 0.035 0.055 0.053 0.043 0.043		96 84 89 NA 81 91 85 89 90 94 90
на предокала () - () на плед за () - () на		Prese-1a	352 144 469 32 324 467 94 498 157 1537 433	358 150 475 39 330 503 504 163 165 163	-0096 0,001 0,005 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001	-0.014 -0.014 -0.014 -0.014 -0.014 -0.014 -0.019 -0.022 -0.025 -0.026 -0.020	.034 .047 .047 .047 .047 .047 .047 .047 .04	.0.021 0 0.020 0 .0.010 0 0.021 0 0.024 0 0.024 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.026 0 0.027 0 0.027 0 0.028 0 0.029 0 0.029 0 0.029 0	0.0100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	A.343 I A.343 I A.343 I A.344 I A.344 I A.345 I A.344 I A.345 I A.345	base BL 202 (** 5) base BL 202 (** 5) base Act, collectual (** - 1)	AAAAAUUUUAAUUUAAUUUA Beer 1a AAAAUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU	100 141 124 3 94 25 331 190 59 494 375	195 147 130 9 100 31 337 204 65 500 381		1 1 0.041 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.020 0.0 0.021 0.0 0.021 0.0	9 0.037 97 0.029 157 0.029 15 0.000 15 0.000 17 -0.041 10 0.121 16 0.014 10 0.121 16 0.015 17 0.023 18 -0.001 101 -0.001	0.029 0.029 0.034 0.034 0.034 0.034 0.035 0.035 0.036 0.037 0.036 0.037 0.036 0.037 0.036 0.037 0.043 0.043 0.049	- 0.09 - 0.05 - 0.024 - 0.024 - 0.024 - 0.025 - 0.025 - 0.055 - 0.055 - 0.055 - 0.055 - 0.055 - 0.057 - 0.07	95 84 89 NA 81 91 85 85 89 94 90 83
1)		Prese-1a Prese-1a Prese-1a Brese-1a Brese-1a Prese-1a	352 144 469 32 324 497 94 498 157 150 157 433 306	358 150 475 39 330 503 503 503 100 504 163 156 163 439 312	-0096 0,001 0,005 0,003 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,007 0,005 0,	-0.014 -0.014 -0.014 -0.014 -0.014 -0.033 -0.039	-034 -034 -047 -0166 -031 -035	.0023 2 0.020 2 0.017 2 0.019 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.027 2 0.028 2 0.029 2 0.020 2	0.010	A.101 I A.012 I A.017 I A.111 I A.112 I A.112 I A.113 I A.114 I A.115 I A.114 I A.115 I A.114 I A.115 I A.114 I A.115 I A.155	baseline.2020 -53 baseline.2020 -57 baseline.2020 -7 baseline.2020 -7 <t< td=""><td>Bits Bits <td< td=""><td>188 141 124 3 94 25 331 196 59 59 494 335</td><td>195 147 130 9 100 31 204 65 500 381</td><td></td><td></td><td>99 0.037 97 0.029 157 0.029 15 0.000 15 0.000 16 0.001 16 0.012 16 0.012 17 0.041 10 0.121 10 0.121 10 0.015 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.014 11 0.003</td><td>0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.056 0.057 0.053 0.054 0.043 0.043 0.049</td><td>-0.09 -0.09 -0.09 -0.00 -0.00 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005</td><td>96 84 89 NA 81 91 85 85 89 90 90 83</td></td<></td></t<>	Bits Bits <td< td=""><td>188 141 124 3 94 25 331 196 59 59 494 335</td><td>195 147 130 9 100 31 204 65 500 381</td><td></td><td></td><td>99 0.037 97 0.029 157 0.029 15 0.000 15 0.000 16 0.001 16 0.012 16 0.012 17 0.041 10 0.121 10 0.121 10 0.015 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.014 11 0.003</td><td>0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.056 0.057 0.053 0.054 0.043 0.043 0.049</td><td>-0.09 -0.09 -0.09 -0.00 -0.00 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005</td><td>96 84 89 NA 81 91 85 85 89 90 90 83</td></td<>	188 141 124 3 94 25 331 196 59 59 494 335	195 147 130 9 100 31 204 65 500 381			99 0.037 97 0.029 157 0.029 15 0.000 15 0.000 16 0.001 16 0.012 16 0.012 17 0.041 10 0.121 10 0.121 10 0.015 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.013 10 0.014 11 0.003	0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.056 0.057 0.053 0.054 0.043 0.043 0.049	-0.09 -0.09 -0.09 -0.00 -0.00 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005	96 84 89 NA 81 91 85 85 89 90 90 83
Han maintain an ann an Anna Anna Anna Anna Anna A		Prese-1a Prese-1a Prese-1a Brese-1a Brese-1a Prese-1a Prese-1a Prese-1a Prese-1a </td <td> 352 144 469 324 497 94 498 157 157 157 433 366 </td> <td>358 150 475 39 503 503 100 504 163 163 163 439 312</td> <td>-0096 0001 0.0000 0.0000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000</td> <td>-0.014 -0.013 0.044 -0.033 -0.032 -0.022 0.045 -0.020 0.011 -0.017</td> <td>-034 -044 -047 -047 -047 -049 -049 -049 -049 -049 -049 -049</td> <td>.0023 0 0.020 0 .0110 0 0.037 0 0.039 0 0.039 0 0.030 0 0.031 0 0.032 0 0.031 0 0.032 0 0.033 0 0.034 0 0.035 0</td> <td>0.010 </td> <td>0.101 0 0.017 0 0.017 0 0.010 0 0.011 0 0.012 0 0.013 0 0.014 0 0.015 0 0.016 0 0.017 0 0.018 0 0.019 0 0.011 0 0.012 0 0.015 0</td> <td>baseline 200 (-5) baseline 200 (-7) baseline 200 (-7)</td> <td>Amatematical and a construction of a constr</td> <td>188 141 124 3 94 35 331 196 59 494 375 375</td> <td>195 147 130 9 100 31 337 65 500 381 399</td> <td></td> <td>nm nm nm nm</td> <td>9 0.037 97 0.029 15 0.000 15 0.000 16 0.017 17 -0.041 180 0.0121 180 0.0121 181 0.015 183 0.015 193 0.023 193 0.023 193 0.024 193 0.023 193 0.024 193 0.024 193 0.024</td> <td>0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.056 0.056 0.057 0.054 0.043 0.043 0.054</td> <td>-0.009 -0.057 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.055 -0.055 -0.055 -0.127 -0.129 -0.242 -0.245</td> <td>96 84 89 NAA 81 91 85 85 90 94 90 83 85</td>	 352 144 469 324 497 94 498 157 157 157 433 366 	358 150 475 39 503 503 100 504 163 163 163 439 312	-0096 0001 0.0000 0.0000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000	-0.014 -0.013 0.044 -0.033 -0.032 -0.022 0.045 -0.020 0.011 -0.017	-034 -044 -047 -047 -047 -049 -049 -049 -049 -049 -049 -049	.0023 0 0.020 0 .0110 0 0.037 0 0.039 0 0.039 0 0.030 0 0.031 0 0.032 0 0.031 0 0.032 0 0.033 0 0.034 0 0.035 0	0.010	0.101 0 0.017 0 0.017 0 0.010 0 0.011 0 0.012 0 0.013 0 0.014 0 0.015 0 0.016 0 0.017 0 0.018 0 0.019 0 0.011 0 0.012 0 0.015 0	baseline 200 (-5) baseline 200 (-7)	Amatematical and a construction of a constr	188 141 124 3 94 35 331 196 59 494 375 375	195 147 130 9 100 31 337 65 500 381 399		nm nm	9 0.037 97 0.029 15 0.000 15 0.000 16 0.017 17 -0.041 180 0.0121 180 0.0121 181 0.015 183 0.015 193 0.023 193 0.023 193 0.024 193 0.023 193 0.024 193 0.024 193 0.024	0.029 0.029 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.035 0.056 0.056 0.056 0.057 0.054 0.043 0.043 0.054	-0.009 -0.057 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.246 -0.055 -0.055 -0.055 -0.127 -0.129 -0.242 -0.245	96 84 89 NAA 81 91 85 85 90 94 90 83 85
A second se		7mm-1a 7mm-1a 7mm-1a 8mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a	352 144 409 32 324 497 94 157 153 153 355	358 150 475 39 330 503 504 163 156 163 439 312 312	-0096 0,001 0,000 0,	-0.014 -0.013 -0.014 -0.014 -0.014 -0.015 -0.025 -0.026 -0.026 -0.020 0.011 -0.017	-0034 -0044 -0047 -0050 -0	.0.02 .0.02 .0.01 .0.02 .0.010 .0.02 .0.017 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02 .0.02	0.010	0.00 0 0.07 0 0.07 0 0.01 0 0.02 0 0.03 0 0.04 0 0.05 0 0.06 0 0.07 0 0.08 0 0.09 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0	Name, 2020 -53 Name, 47, 2010 -51 Nam, 47, 20	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	198 1 141 1 124 1 3 1 54 1 331 1 199 1 394 1 395 1 397 1 398 1	195 147 130 9 100 31 337 284 65 500 381 399		0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	9 0.037 97 0.029 15 0.000 15 0.000 17 -0.041 18 0.015 16 0.017 16 0.015 13 0.023 14 0.015 15 -0.001 16 -0.001 17 -0.011	0029 0029 0029 0024 0025 0024 0025 0026 0027 0026 0027 0026 0027 0026 0027 0026 0027 0028 0029 0024 0024 0024 0024 0024	-0.009 -0.057 -0.268 -0.268 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005	96 84 89 84 81 81 81 81 81 85 89 90 83 85
An		7mm-1a 7mm-1a 7mm-1a 8mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-1a 7mm-m8 7mm-m8	352 144 409 32 324 497 94 490 1157 130 137 433 306	358 150 475 39 330 503 100 504 163 165 163 439 312 312	-0096 -0091 -0093 -0097 -0097 -0095 -0097 -0095 -0097 -0	-0096 -0093 -0096 -0094 -0099 -0099 -0099 -0099 -0099 -0099 -0099 -0099 -0099		.0.020 0 0.030 0 0.010 0 0.017 0 0.019 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0 0.010 0	0.010 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00 0 0.07 0 0.07 0 0.01 0 0.01 0 0.01 0 0.01 0 0.01 0 0.02 0 0.03 0 0.04 0 0.05 0 0.05 0	Baselli, 22 (C = 5) Baselli, 22 (C = 7) Baselli	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	198 1 141 1 124 1 3 1 3 1 75 1 99 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1 190 1	195 147 130 9 100 31 337 204 65 300 301 9		0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.002 0.000 0.002 0.000 0.002 0.000	9 0.037 57 0.029 15 0.000 16 0.029 177 -0.041 108 0.029 109 -0.041 100 0.121 101 0.015 101 0.015 101 0.015 101 -0.001 101 -0.001	0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0029 0043 0034	-0.001 -0.002 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005	96 84 89 81 81 81 81 81 81 83 85 89 90 83 85

FIGURE 4 Loss of circ-0067724 or circ-0016213 could suppress liver regeneration. (A) Top 26 increased circRNAs in postoperative left liver tissue and eight homologous genes of humans and pigs. (B) Schematic illustration showing the position of the targeting shRNA to knock down the circRNAs. (C) MTT assays to detect the function of shcircRNA. (D,E) qRT-PCR was used to confirm the knock down efficacy in HL-7702. (F,G) Potential downstream miRNAs relative to circ-0067724 or circ-0016213. The quantification is presented as mean \pm SD, *p < 0.05, **p < 0.01, and ***p < 0.001.

more than 2 kb. Almost all of them comprise less than 10 exons (**Figure 3C**). The GC content frequency distribution of the most circRNA is 35–55% (**Figure 3D**). The result showed the circRNA numbers predicted in each sample (**Figure 3E**).

Loss of circ-0067724 or circ-0016213 Could Suppress Liver Regeneration

We focused on increased circRNAs in postoperative left liver tissue and selected 26 increased circRNAs with the greatest variability (**Figure 4A**); however, these were pig circRNAs but not human circRNAs. By homology comparison of the circRNAs and human circRNA sequence, we found eight of them are highly homologous. To further examine whether the eight circRNAs promote liver regeneration, we constructed shRNAs for these eight circRNAs (sh-circRNA) by targeting specific splice junctions (**Figure 4B**). The results from the MTT assays revealed that only knocking down circ-0067724 and circ-0016213, but not the other six, can suppress liver cell proliferation (**Figure 4C**). We used qRT-PCR to confirm the knock down efficacy in HL-7702 (**Figures 4D**,E). Based on the MTT results, we predicted the potential downstream miRNAs relative to circ-0067724 (**Figure 4F**) or circ-0016213 (**Figure 4G**) by Circular RNA Interactome (https://circinteractome.nia.nih.gov/index.html).

DISCUSSION

Primary liver cancer (PLC) is one of the most important public health problems facing the world. The incidence of HCC in the United States has tripled in the past 30 years (El-Serag, 2011).

Hepatectomy is one of the most important treatment methods for liver surgery diseases, especially for primary or metastatic liver malignant tumor diseases; surgical resection is not only the preferred treatment method but also the only possible to achieve a cure (Sucandy et al., 2020). In the past 30 years, with the development of liver surgery, improvement of surgical techniques, and standardization of intraoperative and perioperative management, the restricted area of hepatectomy has been continuously broken through, and the success rate of operation has been significantly improved; in addition, the incidence of postoperative complications and mortality have decreased significantly (Wei Chieh et al., 2020). However, an important factor restricting hepatectomy is insufficient FLR. Postoperative liver failure caused by insufficient FLR is a fatal complication after hepatectomy and one of the common causes of death after extensive hepatectomy. Therefore, how to increase the volume of FLR before surgery and improve the safety of hepatectomy has always been a problem which liver surgery is committed to solve.

The appearance of ALPPS has caused an unprecedented sensation in the field of hepatobiliary surgery. As a new technique of staged hepatectomy, ALPPS will play an important role in promoting the development of hepatobiliary surgery because it is expected to solve the bottleneck problem of hepatectomy, which is insufficient residual liver volume (Fiorentini et al., 2021; Hasselgren et al., 2021). Because ALPPS available time is shorter, the number of cases of clinical implementation is limited; some problems related to ALPPS have yet to be further clarified, such as

the mechanism of significant liver regeneration caused by the joint orthotopic liver partition is unclear and how to reduce the high postoperative complications' incidence and mortality rate. Our research focused on the role of circRNAs in liver regeneration.

CircRNAs have been proven to be widely present in many organs, which are a class of long non-coding RNA molecules, and circRNAs shape a covalently closed continuous loop which have no 5'-3'polarity and contain no polyA tail. CircRNA mainly exists in the cytoplasm or exosomes and has the characteristics of tissue specificity, disease specificity, timing specificity, and high stability (Li et al., 2015). In recent years, a large number of studies have shown that circRNA is closely related to stress response, biological growth and development, and disease occurrence and development, but the specific biological function remains unclear. With the development of research, more and more biological functions of circRNA are recognized (Rong et al., 2017). The miRNAs sponge was the most reported. In our study, we found that eight circRNAs increased after ALPPS, and we predicted the potential downstream miRNAs relative to circ-0067724 or circ-0016213 by Circular RNA Interactome. The two circRNAs may act as miRNA sponges to regulating the expression of downstream target genes of miRNAs. Our study was another example to show the biological functions of circ-0067724 and circ-0016213, which can promote liver regeneration, but the specific mechanisms still need further research.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://www.ncbi.nlm.nih.gov/, SUB10127076.

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of XiangYa Hospital.

AUTHOR CONTRIBUTIONS

YX and LP: experiment, data curation, formal analysis, investigation, and writing—original draft. LG: funding acquisition, methodology, experiment, conceptualization, resources, software, and supervision. All authors: writing—review & editing.

FUNDING

This work was supported by the National Natural Science Foundation of China (81903004), the Natural Science Foundation of Hunan Province (2021JJ41037), and the Scientific Research Project of Hunan Provincial Health Commission (202204010011 and C20180686).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.916286/full#supplementary-material

REFERENCES

- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 68, 394–424. doi:10.3322/caac.21492
- El-Serag, H. B. (2011). Hepatocellular Carcinoma. N. Engl. J. Med. 365, 1118–1127. doi:10.1056/NEJMra1001683
- Fiorentini, G., Ratti, F., Cipriani, F., Quattromani, R., Catena, M., Paganelli, M., et al. (2021). The SMART-ALPPS Protocol: Strategy to Minimize ALPPS Risks by Targeting Invasiveness. *Ann. Surg. Oncol.* 28, 6826–6827. doi:10.1245/ s10434-021-09711-7
- Hasselgren, K., Røsok, B. I., Larsen, P. N., Sparrelid, E., Lindell, G., Schultz, N. A., et al. (2021). ALPPS Improves Survival Compared with TSH in Patients Affected of CRLM. Ann. Surg. 273, 442–448. doi:10.1097/SLA.000000000003701
- Heil, J., and Schadde, E. (2021). Simultaneous Portal and Hepatic Vein Embolization before Major Liver Resection. *Langenbecks Arch. Surg.* 406, 1295–1305. doi:10.1007/s00423-020-01960-6
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global Cancer Statistics. CA A Cancer J. Clin. 61, 69–90. doi:10.3322/caac.20107
- Li, Y., Zheng, Q., Bao, C., Li, S., Guo, W., Zhao, J., et al. (2015). Circular RNA Is Enriched and Stable in Exosomes: A Promising Biomarker for Cancer Diagnosis. *Cell Res.* 25, 981–984. doi:10.1038/cr.2015.82
- Mattiuzzi, C., and Lippi, G. (2020). Cancer Statistics: A Comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). *Eur.* J. Public Health 30, 1026–1027. doi:10.1093/eurpub/ckz216
- Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., et al. (2013). Circular RNAs are a Large Class of Animal RNAs with Regulatory Potency. *Nature* 495, 333–338. doi:10.1038/nature11928
- Narita, M., Oussoultzoglou, E., Ikai, I., Bachellier, P., and Jaeck, D. (2012). Right Portal Vein Ligation Combined with *In Situ* Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-For-Size Settings. *Ann. Surg.* 256, e7–e8. author reply e16-17. doi:10. 1097/SLA.0b013e318265fd51
- Petrowsky, H., Linecker, M., Raptis, D. A., Kuemmerli, C., Fritsch, R., Kirimker, O. E., et al. (2020). First Long-Term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients with Colorectal Liver Metastases. *Ann. Surg.* 272, 793–800. doi:10.1097/SLA.00000000004330
- Rong, D., Sun, H., Li, Z., Liu, S., Dong, C., Fu, K., et al. (2017). An Emerging Function of circRNA-miRNAs-mRNA Axis in Human Diseases. *Oncotarget* 8, 73271–73281. doi:10.18632/oncotarget.19154
- Salim, U., Kumar, A., Kulshreshtha, R., and Vivekanandan, P. (2022). Biogenesis, Characterization, and Functions of Mirtrons. WIREs RNA 13, e1680. doi:10. 1002/wrna.1680
- Schnitzbauer, A. A., Lang, S. A., Goessmann, H., Nadalin, S., Baumgart, J., Farkas, S. A., et al. (2012). Right Portal Vein Ligation Combined with *In Situ* Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-For-Size Settings. *Ann. Surg.* 255, 405–414. doi:10.1097/SLA.0b013e31824856f5

- Shabunin, A. V., Parfenov, I. P., Bedin, V. V., Tavobilov, M. M., Grekov, D. N., Drozdov, P. A., et al. (2020). Specific Complications of Liver Resection and Their Prevention. *Khirurgiia* (Mosk) (3), 5–12. doi:10.17116/ hirurgia20200315
- Siegel, R. L., Miller, K. D., Fuchs, H. E., and Jemal, A. (2021). Cancer Statistics, 2021. CA A Cancer J. Clin. 71, 7–33. doi:10.3322/caac.21654
- Sucandy, I., Giovannetti, A., Spence, J., Ross, S., and Rosemurgy, A. (2020). Robotic Partial Left Hepatectomy for Metastatic Colon Cancer to the Liver. Application of Minimally Invasive Technique in Cancer Surgery. Am. Surg., 3134820952873. doi:10.1177/0003134820952873
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 71, 209–249. doi:10.3322/caac.21660
- Tomassini, F., D'Asseler, Y., Giglio, M. C., Lecluyse, C., Lambert, B., Sainz-Barriga, M., et al. (2019). Hemodynamic Changes in ALPPS Influence Liver Regeneration and Function: Results from a Prospective Study. *HPB (Oxford)* 21, 557–565. doi:10.1016/j.hpb.2018.09.005
- Wei Chieh, A. K., Chan, A., Rotellar, F., and Kim, K.-H. (2020). Laparoscopic Major Liver Resections: Current Standards. *Int. J. Surg.* 82, 169–177. doi:10. 1016/j.ijsu.2020.06.051
- Xiao, Y., Liu, G., Sun, Y., Gao, Y., Ouyang, X., Chang, C., et al. (2020). Targeting the Estrogen Receptor Alpha (ERa)-Mediated circ-SMG1.72/miR-141-3p/Gelsolin Signaling to Better Suppress the HCC Cell Invasion. *Oncogene* 39, 2493–2508. doi:10.1038/s41388-019-1150-6
- Yao, L., Li, C., Ge, X., Wang, H., Xu, K., Zhang, A., et al. (2014). Establishment of a Rat Model of Portal Vein Ligation Combined with *In Situ* Splitting. *PLoS One* 9, e105511. doi:10.1371/journal.pone.0105511
- Zheng, R. S., Sun, K. X., Zhang, S. W., Zeng, H. M., Zou, X. N., Chen, R., et al. (2019). Report of Cancer Epidemiology in China, 2015. *Zhonghua Zhong Liu Za Zhi* 41, 19–28. doi:10.3760/cma.j.issn.0253-3766. 2019.01.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiao, Peng, Xu, Huang, Yang, Liu, Ouyang, Li, Wang, Sheng, Zhai, Lin, Liu and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.